Greater Glasgow and Clyde Medicines

Restrictions:

Restricted to use in accordance with regional protocols [NHS network access required] for the following indications:

• First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.
• Locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen except in patients who do NOT have an activating EGFR mutation.

Prescribing Notes:

Erlotinib is not recommended (and non-Formulary) for the following indications:

• Monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.
• In combination with gemcitabine for the treatment of metastatic pancreatic cancer.

BNF Link